Get to know our clinical trials
Clinical trial of olaptesed pegol with pembrolizumab and nanoliposomal irinotecan or gemcitabine in patients with pancreatic cancer
THE AIM OF THIS STUDY IS TO OBTAIN INFORMATION ON THE EFFECTS OF "OLAPTESED PEGOL" IN COMBINATION WITH THE ANTINEOPLASTIC DRUG PEMBROLIZUMAB, WHEN ADMINISTERED IN COMBINATION WITH REGULAR CHEMOTHERAPY. THE STUDY WILL TEST THE EFFICACY OF THE COMBINATION THERAPY AGAINST END-STAGE PANCREATIC CANCER, SAFETY AND TOLERABILITY. THE STUDY WILL ALSO MEASURE THE AMOUNTS OF OLAPTESED PEGOL IN THE PATIENT'S BODY AT DIFFERENT TIMES AND WHETHER THE PATIENT'S BODY PRODUCES ANTIBODIES AGAINST THE INVESTIGATIONAL DRUG (IMMUNOGENICITY). ANTIBODIES ARE PROTEINS THAT ARE MADE BY THE BODY'S IMMUNE (DEFENSE) SYSTEM TO FIGHT INFECTIONS BY BINDING TO OTHER PROTEINS AND MOLECULES. ANTIBODIES AGAINST OLAPTESED PEGOL COULD REDUCE THE AMOUNT OF THE DRUG IN THE BLOOD AND ITS EFFECTS ON CANCER.
Technical Summary
- Code EudraCT: 2021-001963-25
- Protocol number: SNOXA12C701
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.